Nt2innvovate , It is always good to see your posts

Nt2innvovate , It is always good to see your posts , being that you are also a physician , I like to hear your feelings about many things.

I don't know if the indications/mechanism is not important because during CC , I think March of 2024 ,
Tyler Blok was talking about our patents and he said..

" --We've gotten levels of IP protection surrounding the use of leronlimab and the treatment of HIV. That wont start to expire until 2035.
--We have method of action associated with cancer indication and methods of use , and those start to expire in 2040.
--And then Covid , we have certain protections that again would start to expire in 2040.
--And then most recently developed IP surrounding NASH would not even start to expire in 2043.
So our approach to that IP and what technically started to expire would allow people to use leronlimab antibody for research purposes.
But the practical reality is we we've build up adequate protections around the applications of leronlimab and HIV , Covid , NASH,
And then there are also some certain methods of action IP that would prevent antibody from substantially competing with us while using the wrong amount of antibodies "

The above is a transcript from this CC...

And off label treatment , knowing doctors will be going on , Lets approve any first approval..














--